Details:
Under the the license, Jaguar has to initiate Phase 2 study of NP-500 under an investigational new drug application with the U.S. FDA or an IND-equivalent dossier within six months of April 15, 2020.
Lead Product(s): NP-500
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Atlas Sciences
Deal Size: $1.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 16, 2020